Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

ough 36 weeks post-menstrual age (PMA), and

* fewer days on mechanical ventilation.

Dr. Bose commented, "The data from this Phase 2 estimation trial are encouraging. These data support the continued evaluation of Surfaxin as a therapeutic option for the prevention of BPD."

Discovery's Phase 2 clinical trial enrolled 136 premature infants. In addition to standard of care, patients were randomized to receive either Surfaxin standard dose (175 mg/kg), Surfaxin low dose (90 mg/kg), or sham air as a control. The trial was designed as an estimation study to evaluate the safety and potential efficacy of Surfaxin in infants at risk for BPD, and was not powered to determine statistically significant differences in outcomes. The Surfaxin standard dose (175 mg/kg) is the dose that was administered in Discovery's RDS Phase 3 clinical trials. No meaningful conclusions could be drawn from the Surfaxin low dose (90 mg/kg) treatment group, as infants randomized to this arm had more pre-existing medical risk factors compared with the Surfaxin standard dose (175 mg/kg) group and the control group.

Aerosurf(tm) (aerosolized KL-4 surfactant) delivered via the Chrysalis Technologies novel capillary aerosol generator device

Data from previously conducted pre-clinical studies using aerosolized KL-4 surfactant were also presented to the medical community for the first time. In these studies, KL-4 surfactant was aerosolized to compare Chrysalis' novel, investigational capillary aerosol generator technology to commercially available aerosol generator devices. The studies demonstrated that Aerosurf maintains its chemical structure and essential functional activity post-aerosolization. In addition, the Chrysalis investigational capillary aerosol generator technology generated a nearly 10-fold higher aerosol output rate than the other study devices.

Discovery Labs, in collaboration with Chrysalis, is developing an integrated drug device system that comb
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... REDWOOD CITY, Calif., Aug. 3, 2015 AcelRx ... company focused on the development and commercialization of innovative ... a business update and reported financial results for the ... Business highlights include: , On July 23, ... (CHMP) adopted a positive opinion for Zalviso™ for the ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... July 19, 2011 Spanish drug companies face a ... the United States.  From regulatory (FDA) and GMP compliance, ... there are many areas that must be coordinated.  Those ... company KIM and U.S. company VPCI have entered into ...
... July 19, 2011 Reportlinker.com announces that ... in its catalogue: The ... Discovery http://www.reportlinker.com/p0574968/The-Changing-Role-of-Natural-Products-in-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... This report reveals how natural products have ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2The Changing Role of Natural Products in Drug Discovery 2The Changing Role of Natural Products in Drug Discovery 3The Changing Role of Natural Products in Drug Discovery 4
(Date:8/4/2015)... ... 04, 2015 , ... An article published July 27th by the ... method for encouraging people to lose weight. Specifically the study compared control patients with ... success, adding a financial incentive to the overall incentive of increased health. According to ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard to ... & Day Spa in Santa Barbara, CA is offering the solution by offering ... permanently eliminates sweat and odor glands in the underarms. This simple and permanent ...
(Date:8/4/2015)... ... 04, 2015 , ... Seedstock’s 4th Annual Sustainable Agriculture Conference, ... 2015, at UC San Diego, will explore innovations that farmers and entrepreneurs are ... resources efficiently against the dueling backdrop of a lingering Western drought and burgeoning ...
(Date:8/4/2015)... ... August 04, 2015 , ... Members receiving care from a ... – at a cost that is nine percent lower -- than those members at ... of New Jersey’s patient-centered programs. , “The promise of patient-centered, or value-based, care ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are ... calling a physician. In an effort to share more and better information with ... Pennsylvania to publicly share patient satisfaction ratings and comments about its doctors and ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... Hispanic youth report better dental health habits than their non-Hispanic ... researchers at Columbia University Mailman School of Public Health. ... the Journal of Health Care for the Poor and Underserved, ... community in America. , The study, a snapshot of more ...
... increase cancer growth, cause stroke and heart attacks, revised ... The U.S. Food and Drug Administration on Thursday approved ... which are drugs used to treat certain types of ... and Procrit, and detail their dangers to patients with ...
... Health, Inc.,(Nasdaq: VTIV ) today announced that ... at the 2007 Credit Suisse Healthcare Conference,taking place ... conference will,feature companies spanning all sectors of healthcare, ... presentation will take place on Tuesday, November 13 ...
... Nov. 8 Law Offices of Howard G. Smith,announces ... a lead plaintiff in,the securities class action lawsuit filed ... Micrus Endovascular Corporation ("Micrus" or,the "Company")(Nasdaq: MEND ) ... "Class Period"). The shareholder lawsuit is pending in,the United ...
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced today ... present a corporate overview at the,Lazard Fourth Annual Healthcare ... Time) at the New York Palace Hotel. To ... log on to http://www.monogrambio.com and go to ...
... injury, study finds , THURSDAY, Nov. 8 (HealthDay News) ... may cut their risk for fracture, Canadian researchers report. ... an increased risk of additional fractures, other health problems, ... osteoporosis patients are hip, spine, and wrist fractures. ...
Cached Medicine News:Health News:Study of minority New York City youth finds unequal burden of poor dental health 2Health News:FDA Issues New Warnings for Anemia Drugs 2Health News:FDA Issues New Warnings for Anemia Drugs 3Health News:inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference 2Health News:Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference 2Health News:Sticking With Meds Lowers Elderly Fracture Risk 2
... copolymer is an absorbable co-polymer synthesized ... and 18% glycolic acid. Unlike the ... 100% poly-L-lactic acid (PLLA) or 100% ... substantially amorphous (without crystallinity), meaning that ...
... POLYSORB™ Soft Tissue Anchor 3 mm is a ... to bone using sutures. The resorbable repair device ... bone, and is used to attach soft tissue. ... copolymer, derived from glycolide and lactide colored with ...
Umbrella Cancellous Harpoon...
... anchor is generally utilized when a surgeon would ... bone. Unlike other anchors that require the surgeon ... have that limitation. The only instrument required to ... The 4.4mm Stainless Steel Anchor is packaged sterile ...
Medicine Products: